Case  ||| S:0 E:5 ||| NN
report ||| S:5 E:11 ||| NN
:  ||| S:11 E:13 ||| :
Treatment  ||| S:13 E:23 ||| NNP
failure  ||| S:23 E:31 ||| NN
in  ||| S:31 E:34 ||| IN
a  ||| S:34 E:36 ||| DT
case  ||| S:36 E:41 ||| NN
of  ||| S:41 E:44 ||| IN
aquagenic  ||| S:44 E:54 ||| FW
syringeal  ||| S:54 E:64 ||| FW
acrokeratoderma  ||| S:64 E:80 ||| FW
Aquagenic  ||| S:80 E:90 ||| FW
syringeal  ||| S:90 E:100 ||| FW
acrokeratoderma  ||| S:100 E:116 ||| FW
( ||| S:116 E:117 ||| -LRB-
ASA ||| S:117 E:120 ||| NNP
)  ||| S:120 E:122 ||| -RRB-
is  ||| S:122 E:125 ||| VBZ
a  ||| S:125 E:127 ||| DT
rare ||| S:127 E:131 ||| JJ
,  ||| S:131 E:133 ||| ,
acquired ||| S:133 E:141 ||| VBN
,  ||| S:141 E:143 ||| ,
recurrent ||| S:143 E:152 ||| NN
,  ||| S:152 E:154 ||| ,
and  ||| S:154 E:158 ||| CC
transient  ||| S:158 E:168 ||| JJ
type  ||| S:168 E:173 ||| NN
of  ||| S:173 E:176 ||| IN
keratoderma  ||| S:176 E:188 ||| NNS
that  ||| S:188 E:193 ||| WDT
may  ||| S:193 E:197 ||| MD
occur  ||| S:197 E:203 ||| VB
after  ||| S:203 E:209 ||| IN
a  ||| S:209 E:211 ||| DT
few  ||| S:211 E:215 ||| JJ
minutes  ||| S:215 E:223 ||| NNS
of  ||| S:223 E:226 ||| IN
exposure  ||| S:226 E:235 ||| NN
to  ||| S:235 E:238 ||| TO
water ||| S:238 E:243 ||| NN
.  ||| S:243 E:245 ||| .
Herein ||| S:245 E:251 ||| NNP
,  ||| S:251 E:253 ||| ,
an  ||| S:253 E:256 ||| DT
18-year-old  ||| S:256 E:268 ||| JJ
male  ||| S:268 E:273 ||| JJ
patient  ||| S:273 E:281 ||| NN
who  ||| S:281 E:285 ||| WP
had  ||| S:285 E:289 ||| VBD
bilateral  ||| S:289 E:299 ||| JJ
swelling  ||| S:299 E:308 ||| NN
and  ||| S:308 E:312 ||| CC
whitish  ||| S:312 E:320 ||| JJ
plaques  ||| S:320 E:328 ||| NN
on  ||| S:328 E:331 ||| IN
his  ||| S:331 E:335 ||| PRP$
palms  ||| S:335 E:341 ||| NNS
and  ||| S:341 E:345 ||| CC
soles  ||| S:345 E:351 ||| NN
is  ||| S:351 E:354 ||| VBZ
presented ||| S:354 E:363 ||| VBN
.  ||| S:363 E:365 ||| .
The  ||| S:365 E:369 ||| DT
lesions  ||| S:369 E:377 ||| NN
on  ||| S:377 E:380 ||| IN
soles  ||| S:380 E:386 ||| NN
and  ||| S:386 E:390 ||| CC
heels  ||| S:390 E:396 ||| NNS
developed  ||| S:396 E:406 ||| VBN
within  ||| S:406 E:413 ||| IN
short  ||| S:413 E:419 ||| JJ
time  ||| S:419 E:424 ||| NN
of  ||| S:424 E:427 ||| IN
immersion  ||| S:427 E:437 ||| NN
in  ||| S:437 E:440 ||| IN
water  ||| S:440 E:446 ||| NN
and  ||| S:446 E:450 ||| CC
resolved  ||| S:450 E:459 ||| VBN
after  ||| S:459 E:465 ||| IN
30  ||| S:465 E:468 ||| CD
min  ||| S:468 E:472 ||| NN
with  ||| S:472 E:477 ||| IN
drying ||| S:477 E:483 ||| VBG
.  ||| S:483 E:485 ||| .
In  ||| S:485 E:488 ||| IN
this  ||| S:488 E:493 ||| DT
case ||| S:493 E:497 ||| NN
,  ||| S:497 E:499 ||| ,
all  ||| S:499 E:503 ||| DT
treatment  ||| S:503 E:513 ||| NN
methods ||| S:513 E:520 ||| NNS
,  ||| S:520 E:522 ||| ,
previously  ||| S:522 E:533 ||| RB
described  ||| S:533 E:543 ||| VBN
in  ||| S:543 E:546 ||| IN
the  ||| S:546 E:550 ||| DT
literature  ||| S:550 E:561 ||| NN
in  ||| S:561 E:564 ||| IN
similar  ||| S:564 E:572 ||| JJ
cases  ||| S:572 E:578 ||| NNS
( ||| S:578 E:579 ||| -LRB-
i.e. ||| S:579 E:583 ||| FW
,  ||| S:583 E:585 ||| ,
aluminum  ||| S:585 E:594 ||| NN
salts ||| S:594 E:599 ||| NN
,  ||| S:599 E:601 ||| ,
urea-salicylic  ||| S:601 E:616 ||| JJ
acid  ||| S:616 E:621 ||| NN
including  ||| S:621 E:631 ||| VBG
ointments ||| S:631 E:640 ||| NN
,  ||| S:640 E:642 ||| ,
iontophoresis ||| S:642 E:655 ||| NN
,  ||| S:655 E:657 ||| ,
and  ||| S:657 E:661 ||| CC
botulinum  ||| S:661 E:671 ||| JJ
toxin ||| S:671 E:676 ||| NN
)  ||| S:676 E:678 ||| -RRB-
were  ||| S:678 E:683 ||| VBD
ineffective ||| S:683 E:694 ||| JJ
.  ||| S:694 E:696 ||| .
ASA  ||| S:696 E:700 ||| NNP
is  ||| S:700 E:703 ||| VBZ
a  ||| S:703 E:705 ||| DT
condition  ||| S:705 E:715 ||| NN
that  ||| S:715 E:720 ||| WDT
has  ||| S:720 E:724 ||| VBZ
an  ||| S:724 E:727 ||| DT
adverse  ||| S:727 E:735 ||| JJ
effect  ||| S:735 E:742 ||| NN
on  ||| S:742 E:745 ||| IN
life  ||| S:745 E:750 ||| NN
quality ||| S:750 E:757 ||| NN
.  ||| S:757 E:759 ||| .
Alternative  ||| S:759 E:771 ||| JJ
treatments  ||| S:771 E:782 ||| NNS
are  ||| S:782 E:786 ||| VBP
needed  ||| S:786 E:793 ||| VBN
in  ||| S:793 E:796 ||| IN
ASA  ||| S:796 E:800 ||| NNP
cases  ||| S:800 E:806 ||| NNS
who  ||| S:806 E:810 ||| WP
are  ||| S:810 E:814 ||| VBP
resistant  ||| S:814 E:824 ||| VBN
to  ||| S:824 E:827 ||| TO
treatment  ||| S:827 E:837 ||| NN
modalities  ||| S:837 E:848 ||| VBZ
mentioned  ||| S:848 E:858 ||| VBN
in  ||| S:858 E:861 ||| IN
the  ||| S:861 E:865 ||| DT
literature ||| S:865 E:875 ||| NN
.  ||| S:875 E:877 ||| .
